Oral paliperidone: A review of its use in the management of schizoaffective disorder

CNS Drugs

Volumn 25, Issue 6, 2011, Pages 523-538

  Yang, Lily P H ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Schizoaffective disorder

Indexed keywords

AMIODARONE; BENZATROPINE; BUTYROPHENONE; CLOZAPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ESZOPICLONE; LEVODOPA; LITHIUM; LORAZEPAM; MEFLOQUINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; PALIPERIDONE; PAROXETINE; PHENOTHIAZINE; PLACEBO; QUETIAPINE; QUINIDINE; RIFAMPICIN; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SOTALOL; TRAMADOL; TRIMETHOPRIM; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZALEPLON; ZOLPIDEM; ZOPICLONE;

AGITATION; AKATHISIA; ANORGASMIA; AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; GALACTORRHEA; GLUCOSE BLOOD LEVEL; HUMAN; INSOMNIA; LIBIDO DISORDER; MASTALGIA; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; NAUSEA; PATIENT COMPLIANCE; PHARMACODYNAMICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RESTLESSNESS; RHINOPHARYNGITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ADMINISTRATION, ORAL; HUMANS; ISOXAZOLES; PSYCHOTIC DISORDERS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 79958241190     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11207440-000000000-00000     Document Type: Article

References (63)

1. Kantrowitz JT, Citrome L. Schizoaffective disorder: a re- view of current research themes and pharmacological management. CNS Drugs 2011; 25 (4): 317-31.
2. Malhi GS, Green M, Fagiolini A, et al. Schizoaffective dis- order: diagnostic issues and future recommendations. Bipolar Disord 2008 Feb; 10 (1 Pt 2): 215-30.
3. Laursen TM, Agerbo E, Pedersen CB. Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index. J Clin Psychiatry 2009 Oct; 70 (10): 1432-8.
4. Cheniaux E, Landeira-Fernandez J, Lessa Telles L, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord 2008 Mar; 106 (3): 209-17.
5. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2010; 71 Suppl. 2: 20-6.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
7. Jager M, Becker T, Weinmann S, et al. Treatment of schi- zoaffective disorder: a challenge for evidence-based psychiatry. Acta Psychiatr Scand 2010 Jan; 121 (1): 22-32.
8. Gersing K, Burchett B, Turner N, et al. Identifying unique characteristics of schizoaffective disorder [poster]. 21st US Psychiatric and Mental Health Congress; 2009 Nov 2-5; Las Vegas (NV).
9. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007 Jan; 64 (1): 19-28. (Pubitemid 46041735)
10. Vieta E. Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. J Clin Psychiatry 2010; 71 Suppl. 2: 14-9.
11. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Invega® (pa- liperidone) extended-release tablets: US prescribing information [online]. Available from URL: http://invega. com/assets/prescribing-information.pdf [Accessed 2011 May 24].
12. Janssen-Cilag Ltd. Invega 1.5mg, 3mg, 6mg, 9mg, 12mg prolonged-release tablets: summary of product characteristics [online]. Available from URL: http://www.medicines. org.uk/EMC/medicine/19828/SPC/INVEGA+1.5+mg%2c+ 3+mg%2c+6+mg%2c+9+mg%2c+12+mg+prolonged-release+ tablets/[Accessed 2011 May 24].
13. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006 Oct; 22 (10): 1879-92. (Pubitemid 44663390)
14. Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 2010; 70 (10): 1295-317.
15. Canuso CM, Battisti WP. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schi-zoaffective disorder and bipolar mania. Expert Opin Pharmacother 2010 Oct; 11 (15): 2557-67.
16. Hoy SM, Scott LJ, Keating GM. Intramuscular paliper- idone palmitate. CNS Drugs 2010; 24 (3): 227-44.
17. Richelson E. New antipsychotic drugs: how do their recep- tor-binding profiles compare? J Clin Psychiatry 2010 Sep; 71 (9): 1243-4.
18. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000 Nov 24; 68 (1): 29-39.
19. Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008 Apr; 197 (2): 229-35.
20. Luthringer R, Staner L, Noel N, et al. A double-blind, pla- cebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007 Sep; 22 (5): 299-308. (Pubitemid 47237549)
21. Schwartzer JJ, Morrison RL, Ricci LA, et al. Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression. Psychopharmacology (Berl) 2009; 203 (4): 653-63.
22. Corena-McLeaod MdP, Oliveros A, Charlesworth C, et al. Paliperidone as a mood stabilizer: a pre-frontal cortex sy-naptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res 2008 Oct 3; 1233: 8-19.
23. Schmidt AJ, Krieg JC, Clement HW, et al. Effects of que- tiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro. J Psychopharmacol 2010 Mar; 24 (3): 349-54.
24. Zhu HJ, Wang JS, Markowitz JS, et al. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neu-ropsychopharmacology 2007 Apr; 32 (4): 757-64. (Pubitemid 46426181)
25. Boom S, Talluri K, Janssens L, et al. Single- and multiple- dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009 Nov; 49 (11): 1318-30.
26. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new mono-aminergic antagonist, in humans. Drug Metab Dispos 2008 Apr; 34 (4): 769-79. (Pubitemid 351468385)
27. Thyssen A, Cleton A, van Osselaer N, et al. Effects of renal impairment on the pharmacokinetic profile of paliperidone extended-release tablets [poster]. 3rd Pharmaceutical Sciences World Congress; 2007 Apr 22-25; Amsterdam.
28. Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliper-idone. Int J Clin Pharmacol Ther 2009 Oct; 47 (10): 606-16.
29. Cleton A, Rossenu S, Boom S, et al. Evaluation of the pharmacokinetics of paliperidone extended-release tablets in healthy elderly subjects [poster]. 3rd Pharmaceutical Sciences World Congress; 2007 Apr 22-25; Amsterdam.
30. Berwaerts J, Cleton A, Herben V, et al. The effects of par- oxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009 Jul; 42 (4): 158-63.
31. Thyssen A, Cleton A, Talluri K, et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psycho-pharmacol 2009 Oct; 24 (7): 532-9.
32. Canuso CM, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol 2010 Oct; 30 (5): 487-95.
33. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010 May; 71 (5): 587-98.
34. Canuso CM, Turkoz I, Fu DJ, et al. Role of paliperidone extended-release in treatment of schizoaffective disorder. Neuropsychiatr Dis Treat 2010 Oct; 6: 667-79.
35. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008; 69 (5): 817-29. (Pubitemid 351838691)
36. Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008 Nov; 23 (6): 343-56.
37. Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol 2010 Nov; 25 (6): 334-41.
38. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23 (6): 477-92.
39. Kramer M, Simpson G, Maciulis V, et al. Paliperidone ex- tended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007 Feb; 27 (1): 6-14. (Pubitemid 46105757)
40. Duggal HS. Possible neuroleptic malignant syndrome asso- ciated with paliperidone [letter]. J Neuropsychiatry Clin Neurosci 2007 Fall; 19 (4): 477-8. (Pubitemid 350156116)
41. Mantas C, Kalabokis G, Goulia P,et al. Possible neuroleptic malignant syndrome during paliperidone administration: a case report [letter]. J Clin Psychopharmacol 2010 Feb; 30 (1): 89-91.
42. Han C, Lee SJ, Pae CU. Paliperidone-associated atypical neuroleptic malignant syndrome: a case report [letter]. Prog Neuropsychopharmacol Biol Psychiatry 2011 Mar; 35 (2): 650-1.
43. Nayak RB, Bhogale GS, Patil NM, et al. Paliperidone- induced neuroleptic malignant syndrome [letter]. J Neuro-psychiatry Clin Neurosci 2011 Fall; 23 (1): E14-5.
44. Hough DW, Natarajan J, Vandebosch A, et al. Evaluation of the effect of paliperidone extended release and quetia-pine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2011 Jan; 26 (1): 25-34.
45. Schreiner A, Tessier C, Hoeben D, et al. A prospective ran- domized controlled trial of paliperidone ER versus oral olan- zapine in patients with schizophrenia [poster]. 18th European Congress of Psychiatry; 2010 Feb 27-Mar 2; Munich.
46. Olfson M, Marcus SC, Wan GJ. Treatment patterns for schizoaffective disorder and schizophrenia among Medi-caid patients. Psychiatr Serv 2009 Feb; 60 (2): 210-6.
47. Malhi GS, Berk M, Bourin M, et al. Atypical mood stabi- lizers: a 'typical' role for atypical antipsychotics. Acta Psychiatr Scand Suppl 2005; 111 Suppl. 426: 29-38. (Pubitemid 40604347)
48. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and ris-peridone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul; 60 (7): 681-90. (Pubitemid 36818630)
49. Keck Jr PE, Reeves KR, Harrigan EP, et al. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001 Feb; 21 (1): 27-35. (Pubitemid 32096747)
50. Glick ID, Mankoski R, Eudicone JM, et al. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord 2009 May; 115 (1-2): 18-26.
51. Janicak PG, Keck Jr PE, Davis JM, et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol 2001 Aug; 21 (4): 360-8. (Pubitemid 32673024)
52. Sajatovic M, Mullen JA, Sweitzer DE. Effiacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002 Dec; 63 (12): 1156-63. (Pubitemid 36084061)
53. Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsycho-pharmacology 2006 Oct; 31 (10): 2318-25. (Pubitemid 44413213)
54. Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002 Jun; 70 (1): 19-26. (Pubitemid 34756609)
55. Kilbourne AM, Brar JS, Drayer RA, et al. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics 2007 Sep-Oct; 48 (5): 412-7. (Pubitemid 47330294)
56. van Winkel R, van Os J, Celic I, et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008 Aug; 69 (8): 1319-27.
57. American Diabetes Association, American Psychiatric Asso- ciation, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27 (2): 596-601.
58. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008 Jan; 13 (1): 27-35. (Pubitemid 350275185)
59. Alvarez-Jimenez M, Gonzalez-BlanchC, Crespo-Facorro B, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008; 22 (7): 547-62. (Pubitemid 351822117)
60. Sheehan JJ, Sliwa JK, Amatniek JC, et al. Atypical antipsychotic metabolism and excretion. Curr Drug Metab 2010 Jul; 11 (6): 516-25.
61. Ortho-McNeil Janssen Scientific Affairs, LLC. A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder [ClinicalTrials.gov identifier NCT01193153]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 May 9].
62. Ortho-McNeil-Janssen Pharmaceuticals Inc. Invega® Sus- tenna® (paliperidone palmitate) extended-release injectable suspension: US prescribing information [online]. Available from URL: http://janssencns.com/shared/pi/ sustenna/in vegasustenna.pdf [Accessed 2011 May 9].
63. Janssen Pharmaceutica N.V. Xeplion 25, 50, 75, 100 and 150mg prolonged release suspension for injection: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/002105/WC 500103317.pdf [Accessed 2011 May 9]